Latest News


€41M for a Rising Star of Synthetic Biology: Ginkgo Bioworks

Once will not hurt, we’ll speak a bit about an inspiring US-based company. A synthetic biology start-up from the worlds biggest biocluster is on its road to success. Shortly after its Series A, Boston-based Ginkgo Bioworks goes on better and raises $45M (€41M). The microbe engineer makes food taste moreish …


Green light for Ascendis’ Phase III in Growth Hormone Deficiency

It seems like the €48M Series D financing and the public introduction on the NASDAQ have paid off. Danish Ascendis Pharma announced positive top-line results from a Phase II study that evaluated the once-weekly TransCon Growth Hormone in children with growth hormone deficiency. After Zosano, Ascendis was the second European …


Hepatitis C: Gilead’s most lucrative drug is facing competition from Medivir

The Gilead’s Hepatitis C cure remains a remedy for rich people. Swedish Medivir AB may contribute to a change in the  situation. Jointly developed with Janssen Pharmaceutical Companies, its NS5B polymerase inhibitor AL-704 will be tested in Phase I and may become a competitor of Gilead‘s Solvadi. Approximately 150 million …


MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance the companies entered into in February 2013. Heptares will use MorphoSys’s antibody library to generate a new candidate targeting a GPCR, one of the largest class of pharmaceutical target currently on the market. In …


UCB’s Lupus treatment breaks down in Phase III

Big disappointment for Belgian UCB. After 9 years of research, its lead candidate in Immunology, designed to treat Systemic Lupus Erythematosus, failed in Phase III.  The drug was acquired from Immunomedics in 2006 and costed at least $38M. Epratuzumab is a monoclonal antibody for the treatment of Systemic Lupus Erythematosus, …

bayer_sprint bioscience

NASDAQ-listed Sprint Bioscience sells early-stage Cancer Treatment to Bayer

Just as Boehringer Ingelheim, Bayer HealthCare expands its cancer portfolio this week. The German company is inclined to shell out €190M for a drug that interacts with the peculiar metabolism of cancer cells. Its developer, Sprint Bioscience AB, is a Swedish company founded in 2009, from former members of AstraZeneca, Biovitrum …


Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Boehringer Ingelheim puts a new pillar in its oncology pipeline. The German giant acquired a Phase II compound for the treatment of lung cancer from the Korean pharma company Hamni. Non-small cell lung cancer makes up about 90% of all lung cancers. A targeted therapy includes the inhibition of the …


How to create a late-stage Biotech company in a record time? Ask Novartis!

Mereo BioPharma. This name doesn’t ring a bell? From now on, you should keep it in mind as it could rapidly become a rising star on the European Biotech scene. Launched five months ago, the company has already three candidates in phase II and just raised $119m (approximately €108m) from …


Erytech follows the path of DBV and Cellectis to enter the US stock exchange

Erytech Pharma, developer of an innovative ‘tumor starvation’ treatment, today announced that it plans to conduct a registered initial public offering in the United States and thus, plays in the major league with its French fellows DBV and Cellectis. It’s definitely the last trend in Biotech! European companies are queuing up to enter …


GenSight raises €33M to treat young adult blindness

GenSight completed a Series B financing of $36 Million (€33M) to accelerate its treatment for blindness in teens. The 11.5 million shares sold by GenSight will turn into common stock, when the French company accomplishes its IPO on the NASDAQ as planned. GenSight Biologics is a biotech company focusing on …


Effective Antibody from a Patient recovering from Middle East Respiratory Syndrome

2 month after the outbreak of the coronavirus in South Korea, researchers are presenting first results of an effective treatment for the Middel East Respiratory Syndrom (MERS). The Swiss biotech Humabs BioMed has been able to isolate an effective antibody from a cured patient that should now be further developed under …


We met Antoine Hubert, CEO of Ynsect and awarded Innovator Under 35 by the MIT

Each year since 1999, MIT Technology Review, the journal from the top-rank US University, discovers new generations of Innovators Under 35. The awarded young leaders are developing new technologies to solve the major global challenges of today in remarkably different ways and impacting the lives of millions of people around …


Event Summaries


Biotech & Medtech well represented at Europe’s largest technological start-up challenge

The second edition of the Hello Tomorrow Conference, a major event dedicated to disruptive technologies and science entrepreneurship, took place last week in Paris. This event gathered scientists, entrepreneurs and investors during two days to share & present the scientific innovations that will shape our future. It gathered 6 different scientific …


BIO2015: Over and Out!

Three is the magic number as they say… After bringing you the highlights of the first and second day of the biggest Biotech Convention worldwide, we couldn’t give up on you so close from the end. So without further ado, here’s the summary of day three. Katrine Bosley, CEO of Editas, hosted Arnt …

Made with & in Berlin
Labiotech UG, All Rights Reserved - Imprint
Designed and developped by Zelie Dethorey